Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigatio
Outcome
OIG enforcement action against Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigatio for false claims, kickbacks, controlled substance. Penalty: $2 million.
Details
Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigatio — OIG Enforcement (2012)
OIG took enforcement action against Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigatio in 2012 involving false claims, kickbacks, controlled substance violations in the Small Manufacturers sector.
Penalty: $2 million
Violation types: False Claims, Kickbacks, Controlled Substance
Entity type: Healthcare Provider
Penalty type: Criminal
Source: Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations
How Crucible Prevents This
Crucible's billing compliance controls enforce documentation-to-claims reconciliation, requiring clinical attestation before claims submission and flagging billing patterns that deviate from documented care delivery. Crucible's referral monitoring tracks patient source patterns and flags arrangements that correlate referral volume with financial relationships, enforcing anti-kickback compliance documentation. Crucible's controlled substance tracking enforces DEA-compliant inventory reconciliation, flags prescribing pattern anomalies, and requires segregation of duties for dispensing and record-keeping.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works